'Miracle' cure for fatness has slim chance of success
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Sunday 30 July 1995
Three separate groups of scientists have shown that mice suffering from inherited obesity dramatically lost weight when injected with a genetically engineered hormone.
But humans do not always react in the same way as mice. Other work, which was not mentioned in the mountain of scientific reports and press releases published last week by companies financing the research, indicates that obese people already have higher-than-average levels of the same hormone. Daily injections, therefore, will not work on them in the dramatic way they worked on mice, whose bodies lack the hormone.
Some obesity scientists believe drug companies have hyped the latest research on obese mice, published on Friday in the journal Science, by suggesting that clinical trials of the hormone may begin as early as next year, with a clinical product on the market by the end of the decade.
The scientist at the centre of the latest research is Jeffrey Friedman of the Howard Hughes Medical Institute at Rockefeller University in New York. Dr Friedman unravelled the chemical nature of the ''ob'' gene for obesity in mice last December and Rockefeller has since established a $20m (pounds 12.5m) deal with Amgen, a Californian biotechnology company, to develop the research into a human drug.
When news of last week's research was leaked prematurely to Wall Street by financial analysts, shares in Amgen rose 10 per cent.
According to scientists close to the Institute, Dr Friedman has given private seminars showing that the ob protein, a hormone, can be detected in all humans. But obese people probably have higher levels compared to lean people. Nobody knows why the hormone, so effective in helping mice lose weight, seems to be associated with the opposite effect in humans. One very speculative possibility is that in the bodies of some obese people, it does not work properly.
When questioned about this work, however, Dr Friedman refused to give details. ''Those experiments are under way,"he said, "and I don't want to give you any information until we know it is correct, so the results are not final yet. The data are too preliminary for me to talk about.''
Dr Friedman and his researchers did, however, release details in their research paper, showing that they were able to measure the ob protein in six members of his own lab. He said these volunteers were all lean and therefore could not be used to compare obese people with slim people.
Developing a drug to ''cure'' obesity has important financial ramifications. In Britain alone an estimated pounds 4bn a year is spent on weight-reducing products and on treating illnesses, such as heart disease, indirectly linked to obesity. Americans spend about $40bn a year on efforts to trim the fat.
Despite the intense interest in the ob gene, however, less than a quarter of the cases of serious obesity are the result of genetic defects. Medical researchers stressed that the biggest culprits behind the doubling of obesity cases in the past 10 years are poor diet and lack of exercise.
Even Dr Friedman said research on obesity in mice could not replace current advice to overweight people: ''Diet and exercise are the mainstays of current treatment, and I would imagine even if this thing were to develop into a useful clinical tool in some circumstances, it would be a supplement to that, and not a replacement.''
See Business section, page 2
- 2 Joan Rivers: 'Palestinians deserve to be dead'
- 3 Lady al-Qa’ida: On the trail of Dr Aafia Siddiqui, the world’s most wanted prisoner
- 4 A teacher speaks out: 'I'm effectively being forced out of a career that I wanted to love'
- 5 It's not just the savagery of Isis that is shocking – its weaponry is too
Robin Williams Emmys tribute led by Billy Crystal criticised for including 'racist' joke about Muslim woman
The Rotherham child abuse scandal is a tale of apologists, misogyny and double standards
What do immigrants really think of Britain? Polish immigrant's Reddit post goes viral
Scottish independence TV debate: Pumped-up Alex Salmond bounces back in bruising second round against Alistair Darling
Do you realise just how foolish the UK looks?
With Douglas Carswell joining Ukip, my party has taken another giant step forward
- < Previous
- Next >
£60000 - £70000 per annum + Benefits + Bonus: Harrington Starr: Senior Data Sc...
Highly Attractive Salary: Austen Lloyd: BRISTOL - This is a very unusual law c...
£28000 - £30000 per annum + Benefits + Bonus: Harrington Starr: Junior VB.NET ...
£40000 - £50000 per annum + Benefits + Bonus: Harrington Starr: C# .NET Web De...